Optune Lua received FDA approval based on data from the pivotal LUNAR trial which demonstrated significant median OS ...

Novocure (NASDAQ: NVCR) announced today that the U.S. Food and Drug Administration (FDA) has approved Optune Lua® for ...

The FDA yesterday the approval of Novocure’s Optune device to include the treatment of metastatic non-small cell lung cancer.

“Novocure is committed to extending ... cancer-related death worldwide1, and non-small cell lung cancer (NSCLC) accounts for approximately 85% of all lung cancers. It is estimated that ...

Highlights:,Significant Stock Surge:,NovoCure's shares rose by 10.7% to $17.78, driven by substantial trading volume following FDA approval of its Optune Lua device for metastatic non-small cell lung ...

Lung cancer remains the leading cause of cancer-related death worldwide, with NSCLC accounting for approximately 85% of all ... Novocure. The FDA approval of Optune Lua for metastatic non-small ...

Optune Lua is designed for adult patients with metastatic non-small cell lung cancer (mNSCLC) who have experienced disease progression after platinum-based chemotherapy. Asaf Danziger, CEO of Novocure ...

Lung cancer remains the leading cause of cancer-related death worldwide, with NSCLC accounting for approximately 85% of all lung ... with non-small cell lung cancer. Analyst firm H.C. Wainwright has ...

Mixed messages about AI?optimistic marketing claims alongside dystopian warnings of potential dangers?make it challenging for the average person to discern what AI is and what its impacts can be. To ...

CeriBell, Inc. ("Ceribell"), a commercial-stage medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, announced today the ...

Alongside immunotherapy or chemo, the wearable device helped patients live longer in a trial, though the results are somewhat controversial.